The FDA has approved finerenone (Kerendia, Bayer) for the treatment of adults with chronic kidney disease (CKD) associated ...

New research to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, ...

FDA has approved Bayer's Kerendia to reduce disease progression risk in adults with chronic kidney disease associated with type 1 diabetes.

New research to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from Sept. 28–Oct. 2 shows that, with the use of continuous glucose ...

A Far North Queensland couple who started their research journey in Cairns are part of a team behind "promising" early ...

Eating only between noon and 8 p.m. improved blood sugar control in a small study of adults with Type 1 diabetes and obesity, ...

The FDA has approved finerenone as a therapy to lower urinary albumin-to-creatinine ratio among adults with chronic kidney ...

Bayer just scored another label expansion for its blockbuster-in-waiting, Kerendia. | The heart and kidney med earned the first FDA nod in three decades for adults with chronic kidney disease ...

FDA expanded finerenone use to CKD with type 1 diabetes to reduce UACR, positioning it as the only MRA indicated across CKD associated with type 1 and type 2 diabetes. FINE-ONE (n=242) showed ...

The FDA has approved Kerendia (finerenone) to reduce UACR, which is expected to slow CKD progression in adults with type 1 diabetes.

Type One Diabetic Welfare Society proposes a Type 1 diabetes registry to enhance care and support across Kerala.